Dyspareunia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Future or investigational therapies== | ==Future or investigational therapies== | ||
potential genetic predisposition to [[chronic inflammation]] among | potential [[genetic predisposition]] to [[chronic inflammation]] among vestibulodynia afflicted women. This [[genetic polymorphism]] leads to a reduced capacity to terminate and to an exaggerated [[inflammatory]] response. More research must be done to suggest a strong [[Genetic linkage|genetic link]] with [[Genito-Pelvic Pain/Penetration Disorder]] (GPPPD).<ref>https://doi.org/10.18192/uojm.v7i2.2198</ref> | ||
==References== | ==References== | ||
Latest revision as of 05:29, 26 September 2020
|
Dyspareunia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dyspareunia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dyspareunia future or investigational therapies |
|
Risk calculators and risk factors for Dyspareunia future or investigational therapies |
Overview
More research must be done to suggest a strong genetic link with Genito-Pelvic Pain/Penetration Disorder (GPPPD).
Future or investigational therapies
potential genetic predisposition to chronic inflammation among vestibulodynia afflicted women. This genetic polymorphism leads to a reduced capacity to terminate and to an exaggerated inflammatory response. More research must be done to suggest a strong genetic link with Genito-Pelvic Pain/Penetration Disorder (GPPPD).[1]